JHVEPhoto/iStock Editorial via Getty Images
Incyte’s (INCY) immunotherapy Monjuvi, developed with Xencor (XNCR), will soon become a first-line option for a common type of lymphoma after late-stage trial data indicated on Saturday that the CD19-targeting monoclonal antibody with other drugs improved cancer-free